PTC Therapeutics | PTCT - Pre Tax Profit


PTC Therapeutics reported $-2.46M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Esperion Therapeutics USD 63.67M 95M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
TG Therapeutics USD 20.36M 24.73M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026